Denecimig

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion. Sales in North America Operations increased by 36% in Danish kroner (36% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 9% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 125.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 32% in Danish kroner (32% at CER) and Obesity care growing by 37% in Danish kroner to DKK 24.9 billion (37% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER).Within R&D, Novo Nordisk successfully completed the phase 3 FRONTIER 2 trial with Mim8, where once-weekly and once-monthly Mim8 demonstrated superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A. In June 2024, Novo Nordisk announced that the ocedurenone CLARION-CKD phase 3 trial was stopped, as ocedurenone failed to meet the primary endpoint.Also within R&D, Novo Nordisk received a Complete Response Letter from the Food and Drug Administration (FDA) for insulin icodec in July. In Obesity care, Novo Nordisk received a positive CHMP opinion, based on the SELECT trial, for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events in the EU.For the 2024 outlook, sales growth is now expected to be 22-28% at CER, and operating profit growth is now expected to be 20-28% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for both sales and operating profit. PROFIT AND LOSSH1 2024H1 2023Growthas reportedGrowthat CER*DKK million Net sales 133,409 107,667 24% 25% Operating profit 57,780 48,895 18% 19% Net profit 45,457 39,242 16% N/ADiluted earnings per share (in DKK) 10.17 8.71 17% N/A* CER: Constant exchange rates (average 2023). Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first half of 2024, which has enabled us to raise the outlook for the full year. The growth is driven by the increased demand for our GLP-1-based diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments. Within R&D, we are very pleased with the first phase 3 trial results with Mim8 and its potential for people living with haemophilia A, and with the recent recommendation for a label extension for cardiovascular risk reduction for Wegovy® in the EU." About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown+45 3079 9289abmo@novonordisk.comLiz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.comDavid Heiberg Landsted+45 3077 6915dhel@novonordisk.comSina Meyer+45 3075 6656azey@novonordisk.comMark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.comIda Schaap Melvold+45 3077 5649idmg@novonordisk.comFrederik Taylor Pitter+45 3075 8259fptr@novonordisk.com Company announcement No 58 / 2024 Attachment PR240807-Q2

Novo Nordisk has shared positive results from a late-stage study of its haemophilia A therapy, Mim8, in adults and adolescents aged 12 years and older. The rare inherited bleeding disorder is caused by a missing or defective clotting factor VIII and accounts for up to 85% of the 1,125,000 global haemophilia cases. The phase 3 FRONTIER 2 trial has been evaluating the safety and efficacy of a once-weekly and once-monthly dose of Novo’s subcutaneously administered therapy to prevent prolonged and spontaneous bleeding in patients with or without inhibitors. It is estimated that up to 30% of haemophilia A patients have inhibitors, an immune system response to the clotting factors in replacement therapy that cause treatment to stop working. According to the results presented at this year’s International Society of Thrombosis and Haemostasis Annual Congress, Mim8 demonstrated a superior reduction in the estimated mean annualised bleeding rate (ABR) of treated bleeds by 97.1% with once-weekly and 98.7% with once-monthly Mim8 in the trial population with no prior prophylaxis treatment. Once-weekly and once-monthly Mim8 prophylaxis also demonstrated a superior reduction in treated bleeds compared to no prior prophylaxis treatment, and zero bleeds were observed in 85.7% of patients treated with once-weekly Mim8 and in 95% of those receiving a once-monthly dose of the therapy. In the study cohort with prior coagulation factor prophylaxis, Mim8 demonstrated a superior reduction in the estimated mean ABR by 48% for once-weekly and 42.6% for once-monthly treatment, and also showed a superior reduction in treated bleeds compared to prior coagulation factor prophylaxis. Zero bleeds were observed in 66.3% of patients in the once-weekly Mim8 treatment arm and 65.3% of those receiving once-monthly Mim8. Novo said it aims to submit Mim8 for the first regulatory approval towards the end of this year. Martin Holst Lange, executive vice president of development at Novo, described the data as “very encouraging”. “With Mim8, we have the potential of offering a substantial proportion of patients the prospect of zero bleeds and convenient dosing flexibility to fit their lifestyles and needs,” he said.